| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jianjun Xu, Etsuko Minobe, Masaki Kameyam. Ca Frontiers in cellular neuroscience. vol 16. 2022-05-02. PMID:35496903. |
ca parkinson's disease (pd), a common neurodegenerative disease characterized by motor dysfunction, results from the death of dopaminergic neurons in the substantia nigra pars compacta (snc). |
2022-05-02 |
2023-08-13 |
Not clear |
| Katarzyna Kaczyńska, Magdalena Ewa Orłowska, Kryspin Andrzejewsk. Respiratory Abnormalities in Parkinson's Disease: What Do We Know from Studies in Humans and Animal Models? International journal of molecular sciences. vol 23. issue 7. 2022-04-12. PMID:35408858. |
parkinson's disease (pd) is the second most common progressive neurodegenerative disease characterized by movement disorders due to the progressive loss of dopaminergic neurons in the ventrolateral region of the substantia nigra pars compacta (snpc). |
2022-04-12 |
2023-08-13 |
human |
| Tao Dang, Wen-Jing Cao, Rong Zhao, Ming Lu, Gang Hu, Chen Qia. ATP13A2 protects dopaminergic neurons in Parkinson's disease: from biology to pathology. Journal of biomedical research. 2022-04-07. PMID:35387901. |
as we all know, pd is a neurodegenerative disease characterized by the loss of da neurons in the substantia nigra pars compacta. |
2022-04-07 |
2023-08-13 |
Not clear |
| Lan-Hsin Nancy Lee, Chen-Syuan Huang, Hsiang-Hao Chuang, Hsing-Jung Lai, Cheng-Kai Yang, Ya-Chin Yang, Chung-Chin Ku. An electrophysiological perspective on Parkinson's disease: symptomatic pathogenesis and therapeutic approaches. Journal of biomedical science. vol 28. issue 1. 2021-12-10. PMID:34886870. |
parkinson's disease (pd), or paralysis agitans, is a common neurodegenerative disease characterized by dopaminergic deprivation in the basal ganglia because of neuronal loss in the substantia nigra pars compacta. |
2021-12-10 |
2023-08-13 |
Not clear |
| Chao Gu, Yajing Chen, Yan Chen, Chun-Feng Liu, Zengyan Zhu, Mei Wan. Role of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson's Disease. Frontiers in aging neuroscience. vol 13. 2021-12-07. PMID:34867296. |
parkinson's disease (pd) is one of the prevalent neurodegenerative diseases associated with preferential loss of dopaminergic (da) neurons in the substantia nigra compacta (snc) and accumulation of α-synuclein in da neurons. |
2021-12-07 |
2023-08-13 |
Not clear |
| Ayumi E Pottenger, Mitchell J Bartlett, Scott J Sherman, Torsten Falk, Helena W Morriso. Evaluation of microglia in a rodent model of Parkinson's disease primed with L-DOPA after sub-anesthetic ketamine treatment. Neuroscience letters. vol 765. 2021-12-03. PMID:34536508. |
parkinson's disease (pd) is a neurodegenerative disease caused by the death of dopaminergic neurons in the substantia nigra pars compacta (snpc), characterized by motor dysfunction. |
2021-12-03 |
2023-08-13 |
rat |
| Hongli Li, Yaru Feng, Ziyu Chen, Xi Jiang, Zhenyu Zhou, Jinfeng Yuan, Fei Li, Yu Zhang, Xingxu Huang, Shengjie Fan, Xiaojun Wu, Cheng Huan. Pepper component 7-ethoxy-4-methylcoumarin, a novel dopamine D2 receptor agonist, ameliorates experimental Parkinson's disease in mice and Caenorhabditis elegans. Pharmacological research. vol 163. 2021-11-18. PMID:33007422. |
parkinson's disease (pd) is a progressive neurodegenerative disease resulting from the degeneration of dopaminergic (daergic) neurons in the substantia nigra pars compacta (snpc) and subsequent deficit of dopamine in the striatum. |
2021-11-18 |
2023-08-13 |
mouse |
| Ruixian Xing, Xuewen Liu, Buxian Tian, Yan Cheng, Longguang L. Neuroprotective effect of Na Drug development research. vol 82. issue 7. 2021-11-15. PMID:33538000. |
neuroprotective effect of na parkinson's disease (pd) is a disabling neurodegenerative disease mainly caused by degeneration of mesencephalic dopaminergic neurons in the substantia nigra pars compacta (snpc). |
2021-11-15 |
2023-08-13 |
Not clear |
| Tapan Behl, Piyush Madaan, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Ahmed Al-Harrasi, Sridevi Chigurupati, Ibrahim Alrashdi, Simona Gabriela Bunga. Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target. International journal of molecular sciences. vol 22. issue 18. 2021-11-01. PMID:34576325. |
one of the utmost frequently emerging neurodegenerative diseases, parkinson's disease (pd) must be comprehended through the forfeit of dopamine (da)-generating nerve cells in the substantia nigra pars compacta (sn-pc). |
2021-11-01 |
2023-08-13 |
Not clear |
| Alexandre Vallée, Jean-Noël Vallée, Yves Lecarpentie. Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells. vol 10. issue 2. 2021-10-15. PMID:33503974. |
parkinson's disease (pd) is one of the major neurodegenerative diseases (nd) which presents a progressive neurodegeneration characterized by loss of dopamine in the substantia nigra pars compacta. |
2021-10-15 |
2023-08-13 |
Not clear |
| Henrik Renner, Hans R Schöler, Jan M Brude. Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond. Movement disorders : official journal of the Movement Disorder Society. 2021-09-20. PMID:34498298. |
parkinson's disease (pd) is the second most common neurodegenerative disease and primarily characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the midbrain. |
2021-09-20 |
2023-08-13 |
human |
| Mustafa T Ardah, Greeshma Bharathan, Tohru Kitada, M Emdadul Haqu. Ellagic Acid Prevents Dopamine Neuron Degeneration from Oxidative Stress and Neuroinflammation in MPTP Model of Parkinson's Disease. Biomolecules. vol 10. issue 11. 2021-09-02. PMID:33172035. |
parkinson's disease (pd) is one of the most common neurodegenerative diseases and is characterized by progressive dopaminergic neurodegeneration in the substantia nigra pars compacta area. |
2021-09-02 |
2023-08-13 |
Not clear |
| Luca Magistrelli, Elena Contaldi, Cristoforo Com. The Impact of Life (Basel, Switzerland). vol 11. issue 8. 2021-08-31. PMID:34440548. |
the impact of parkinson's disease (pd) is a common and progressive neurodegenerative disease, caused by the loss of dopaminergic neurons in the substantia nigra pars compacta in the midbrain, which is clinically characterized by a constellation of motor and non-motor manifestations. |
2021-08-31 |
2023-08-13 |
Not clear |
| Victor A D Holanda, Julia J Didonet, Manara B B Costa, Adriano H do Nascimento Rangel, Edilson D da Silva, Elaine C Gaviol. Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease. Pharmaceuticals (Basel, Switzerland). vol 14. issue 8. 2021-08-31. PMID:34451872. |
parkinson disease (pd) is a neurodegenerative disease mainly characterized by the loss of nigral dopaminergic neurons in the substantia nigra pars compacta. |
2021-08-31 |
2023-08-13 |
rat |
| Eun-Mi Hur, Byoung Dae Le. LRRK2 at the Crossroad of Aging and Parkinson's Disease. Genes. vol 12. issue 4. 2021-08-16. PMID:33805527. |
parkinson's disease (pd) is a heterogeneous neurodegenerative disease characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the widespread occurrence of proteinaceous inclusions known as lewy bodies and lewy neurites. |
2021-08-16 |
2023-08-13 |
Not clear |
| Alexandre Vallée, Jean-Noël Vallée, Yves Lecarpentie. Potential role of cannabidiol in Parkinson's disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation. Aging. vol 13. issue 7. 2021-08-16. PMID:33848261. |
parkinson's disease (pd) is a major neurodegenerative disease (nd), presenting a progressive degeneration of the nervous system characterized by a loss of dopamine in the substantia nigra pars compacta. |
2021-08-16 |
2023-08-13 |
Not clear |
| Falaq Naz, Rahul, Mahino Fatima, Swaleha Naseem, Wasi Khan, Amal Chandra Mondal, Yasir Hasan Siddiqu. Ropinirole silver nanocomposite attenuates neurodegeneration in the transgenic Drosophila melanogaster model of Parkinson's disease. Neuropharmacology. vol 177. 2021-08-12. PMID:32707222. |
parkinson's disease (pd) is a progressive neurodegenerative disease due to the degeneration of dopaminergic neurons in substantia nigra pars compacta of the mid brain. |
2021-08-12 |
2023-08-13 |
drosophila_melanogaster |
| Yeojin Bang, Juhee Lim, Hyun Jin Cho. Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson's disease: clues to early diagnosis and effective treatment. Archives of pharmacal research. vol 44. issue 6. 2021-08-04. PMID:34145553. |
parkinson's disease (pd) is a progressive neurodegenerative disease characterized by movement dysfunction due to selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. |
2021-08-04 |
2023-08-13 |
Not clear |
| Cui Liu, Yan Xue, Mei-Fang Liu, Ying Wang, Lei Che. Orexin and Parkinson's disease: A protective neuropeptide with therapeutic potential. Neurochemistry international. vol 138. 2021-07-30. PMID:32422324. |
parkinson's disease (pd) is the second most common neurodegenerative disease caused by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. |
2021-07-30 |
2023-08-13 |
Not clear |
| Debapriya Garabadu, Nidhi Agrawa. Naringin Exhibits Neuroprotection Against Rotenone-Induced Neurotoxicity in Experimental Rodents. Neuromolecular medicine. vol 22. issue 2. 2021-07-19. PMID:31916219. |
parkinson's disease (pd) is a neurodegenerative disease that is accompanied with the loss of dopaminergic neurons in the substantia nigra pars compacta which subsequently leads to a reduction in the dopamine level in the striatum. |
2021-07-19 |
2023-08-13 |
rat |